Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19862022 | 0.86 | MAPK10 (0.46) | MAOAKDM4EALDH1A1GAAMAPT | |
| SCHEMBL1010472 | 0.85 | MAOA (0.50) | MAOAKDM4EALDH1A1GAAMAPT | |
| SCHEMBL30656741 | 0.85 | MAOA (0.50) | MAOAKDM4EALDH1A1GAAMAPT | |
| SCHEMBL2616773 | 0.81 | MAOA (0.53) | MAOAKDM4EALDH1A1GAAMAPT | |
| SCHEMBL1010625 | 0.78 | MAOA (0.50) | MAOAKDM4EALDH1A1GAAMAPT | |
| SCHEMBL12283552 | 0.78 | MAOA (0.50) | MAOAKDM4EALDH1A1GAAMAPT | |
| SCHEMBL31164726 | 0.78 | MAOA (0.50) | MAOAKDM4EALDH1A1GAAMAPT | |
| SCHEMBL625670 | 0.77 | MAOA (0.58) | MAOAKDM4EALDH1A1GAAMAPT | |
| SCHEMBL875288 | 0.75 | ALDH1A1 (0.60) | MAOAKDM4EALDH1A1GAAMAPT | |
| Hydrochloric Acid SCHEMBL10662272 | 0.74 | ALDH1A1 (0.58) | MAOAKDM4EALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111417635-B | Pyrazolopyrimidines with anti-Respiratory Syncytial Virus (RSV) activity | 爱尔兰詹森科学公司 | 2024-01-02 | — | — | CN | disclosed |
| US-11339165-B2 | Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) | Janssen Sciences Ireland Unlimited Company (IE) | 2022-05-24 | — | — | US | disclosed |
| US-11339165-B2 | Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) | Janssen Sciences Ireland Unlimited Company (IE) | 2022-05-24 | — | — | US | disclosed |
| EP-3717486-B1 | PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2022-03-23 | — | — | EP | disclosed |
| US-20200361942-A1 | PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-19 | — | — | US | disclosed |
| US-20200361942-A1 | PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-19 | — | — | US | disclosed |
| EP-3717486-A1 | PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | Janssen Sciences Ireland Unlimited Company (IE) | 2020-10-07 | — | — | EP | disclosed |
| CN-111417635-A | Pyrazolopyrimidines having activity against Respiratory Syncytial Virus (RSV) | 爱尔兰詹森科学公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-101501036-B | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO KGAA | 2013-04-17 | — | — | CN | disclosed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| CN-101501036-A | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO KGAA (DE) | 2009-08-05 | — | — | CN | disclosed |
| EP-2054416-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361942-A1 | PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | RRP15, MAVS, ACE | MAOA 2470/4885KDM4E 2862/4885ALDH1A1 1980/4885 |
| US-11339165-B2 | Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) | RRP15, MAVS, ACE | MAOA 2470/4885KDM4E 2862/4885ALDH1A1 1980/4885 |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | GRM5, GRM3, GRM1 | MAOA 3070/4885KDM4E 1101/4885ALDH1A1 2895/4885 |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRM3 | MAOA 2896/4885KDM4E 1357/4885ALDH1A1 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.